Cardiovascular, Renal and Metabolic Diseases

Saving lives by jointly addressing cardio-renal-metabolic risks

Our distinctive approach to CVMD

Our core mission is to save the lives of patients by jointly addressing their cardio-renal-metabolic risks. Science is uncovering commonalities between cardiovascular (CV), renal and metabolic diseases (CVMD), explaining why reducing CV risk is so complex. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.  

Our focus is making sure every decision and development is rooted in our ambition to follow the science. We seek to produce medicines that not only provide superior efficacy compared to current treatments in their core indications, but that also help address associated complications. 

Our scientific goal is to slow the progression of CV-related disease, and ultimately, modify or even halt the natural course of the disease itself and regenerate organs.


Our focus on unmet needs

  • Atherosclerosis

    Signs and symptoms do exist for moderate to severe atherosclerosis; however, it may not be diagnosed until after a heart attack or stroke.


  • Heart Failure

    There are 38 million heart failure patients worldwide, with many suffering from at least one other underlying condition such as type-2 diabetes.


  • Renal

    Chronic Kidney Disease (CKD) is a complex, debilitating condition with 200 million adults diagnosed worldwide.


  • Metabolic Disease

    Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 592 million people by the year 2035.


Resources

Addressing the growing unmet need in CVMD

Learn more about our ambition and work in CVMD


Saving lives by jointly addressing cardio-renal-metabolic risks

Watch our unique science-driven strategy in cardiovascular, renal and metabolic diseases come to life


Our CVMD pipeline

We have more than 25 therapies and therapy combinations in our early-to-late stage pipeline in CVMD.


Cardiovascular and Metabolic diseases (as at 27 July 2017)

Phase 1

Phase 1

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular
  • MEDI5884 cardiovascular

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes
  • MEDI6012 cardiovascular
  • verinurad chronic kidney disease

Phase 3

Phase 3

  • Epanova severe hypertriglyceridaemia
  • ZS-9 (sodium-zirconium cyclosilicate) hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with type-2 diabetes and coronary artery disease without a previous history of myocardial infarction or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon BCise weekly autoinjector type-2 diabetes
  • Epanova STRENGTH cardiovascular outcomes study in statin-treated patients at high cardiovascular risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga worsening heart failure or cardiovascular death in patients with chronic heart failure
  • Farxiga/Forxiga renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga type-1 diabetes
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Kombiglyze XR/Komboglyze type-2 diabetes
  • Qtern type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes
  • saxagliptin/dapagliflozin metformin type-2 diabetes

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Atacand, Atacand HCT, Atacand Plus candesartan cilexetil
  • Brilinta/Brilique ticagrelor
  • Bydureon exenatide
  • Byetta exenatide injection
  • Crestor rosuvastatin
  • Farxiga/Forxiga dapagliflozin
  • Kombiglyze XR saxagliptin and metformin XR
  • Komboglyze saxagliptin and metformin HCl
  • Onglyza saxagliptin
  • Plendil, Modip, Splendil, Munobal, Flodil felodipine
  • Seloken ZOK, Toprol-XL, Betaloc ZOK metoprolol succinate
  • Symlin pramlintide acetate
  • Tenormin, Tenormine, Prenormine, Atenol atenolol
  • Zestril lisinopril dihydrate
  • XIGDUO dapagliflozin and metformin HCI
  • XIGDUO XR dapagliflozin and metformin HCI extended-release

Collaboration in CVMD

We are dedicated to engaging with partners in the scientific community to strengthen our commitment to following the science.


Sharing clinical trials information



References

1. Mayo Clinic. Arteriosclerosis / atherosclerosis. http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/symptoms-causes/dxc-20167022. Accessed 15 August 2017.

2. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015; 385 (9970): 812-824.

3. Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Transactions of the American Clinical and Climatological Association. 2014; 125: 229-246.

4. Guariguata L. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice. 2014; 103: 137-149

5. World Health Organization. Global NCD Target: Reduce High Blood Pressure. http://www.who.int/beat-ncds/take-action/policy-brief-reduce-highblood-pressure.pdf

Accessed 15 August 2017. 


Veeva ID: Z4-6503
Date of expiry: August 2018